United States News All stories

Planet Fitness (NYSE:PLNT) reported a surge in year-end membership and same-club sales for 2025, signaling that its low-cost "Judgment Free Zone" model is continuing to capture market share among younger, budget-conscious consumers.

S&P Global (NYSE:SPGI) finalized the sale of its Enterprise Data Management (EDM) and thinkFolio businesses to private equity firm STG on Monday, concluding a divestiture aimed at sharpening the financial giant's focus on its core growth adjacencies.

Lipocine (NASDAQ:LPCN) experimental oral treatment for postpartum depression passed its final independent safety review, clearing the path for a critical data readout later this spring.

Hyperfine (NASDAQ:HYPR), the medical technology firm behind the first portable, AI-powered brain imaging system, reported a dramatic surge in fourth-quarter revenue, signaling a potential turning point for its bedside MRI technology.

Moderna (NASDAQ:MRNA) projected 2025 sales at the upper end of its forecast as a smaller-than-expected decline in U.S. vaccination rates and aggressive cost-cutting help the biotech giant navigate the post-pandemic landscape.

KORU Medical Systems (NASDAQ:KRMD) reported preliminary 2025 revenue that exceeded the high end of its guidance on Monday, as the medical technology firm prepares to pivot from its core immunology business into the high-growth oncology market.

Cellares and Cabaletta Bio (NASDAQ:CABA) announced a landmark regulatory achievement Monday, with the FDA clearing an Investigational New Drug (IND) Amendment to manufacture the autoimmune-focused CAR T therapy, rese-cel, using Cellares’ fully automated platforms.

GeneDx Holdings Corp. (NASDAQ:WGS) issued a bullish outlook for 2026 on Monday, forecasting revenue to exceed the half-billion-dollar milestone as the company’s pivot to high-margin exome and genome sequencing gains unprecedented traction.

DexCom (NASDAQ:DXCM) projected its annual revenue will climb toward $5.25 billion in 2026, marking a pivotal year for the glucose-monitoring leader as it phases out older hardware in favor of its longest-lasting sensor technology to date.

AbbVie (NYSE:ABBV) secured exclusive global rights to a novel cancer-fighting antibody from RemeGen Co. on Monday, marking one of the year’s largest oncology licensing agreements as the pharmaceutical giant moves to integrate next-generation bispecifics with its expanding "ADC" platform.

Shake Shack (NYSE:SHAK) signaled a period of aggressive expansion and improving profitability, issuing an upbeat 2026 outlook that highlights its evolution from a cult favorite to a dominant global restaurant platform.

GTCR announced the completion of its $24.25 billion sale of Worldpay to Global Payments (NYSE:GPN) on Monday, marking the conclusion of a complex three-way transaction that reshapes the landscape of the global payments industry.

SOPHiA GENETICS (NASDAQ:SOPH) reported a record-breaking performance for 2025, driven by a surge in demand for its AI-powered genomic analysis, as the company prepares for a major leadership transition and moves closer to profitability.

Viking Therapeutics (NASDAQ:VKTX) shares were in focus Monday after the company announced the peer-reviewed publication of its Phase 2 VENTURE study results, reinforcing the weight-loss potential of its lead candidate as it enters a pivotal year of Phase 3 testing.

OneSpaWorld Holdings Limited (NASDAQ:OSW) projected its annual revenue will surpass the $1 billion mark for the first time in 2026, as the company streamlines its global operations to capitalize on a record-breaking surge in cruise ship travel.

J.Jill (NYSE:JILL) raised its fourth-quarter and full-year financial guidance on Monday, citing a "stronger-than-anticipated" conclusion to the 2025 holiday season as the retailer prepares for key investor meetings at the ICR Conference.

Zura Bio Limited 9NASDAQ:ZURA) announced it is expanding the patient population for its mid-stage trial of tibulizumab in hidradenitis suppurativa (HS), a move intended to bolster the study’s statistical power as the company prepares for a critical data readout later this year.

Aura Minerals (NASDAQ:AUGO) reported record-breaking preliminary production for the fourth quarter of 2025, bolstered by the successful ramp-up of its Borborema mine and the initial integration of its newest acquisition in Brazil.

Lululemon Athletica (NASDAQ:LULU) raised its fourth-quarter profit and revenue forecasts, signaling that resilient holiday demand for its yoga-inspired apparel is helping the company navigate a cooling U.S. retail environment.

Summit Therapeutics (NASDAQ:SMMT) announced a clinical trial collaboration with GSK (NYSE:GSK) to evaluate the combination of ivonescimab, Summit’s novel investigational PD-1/VEGF bispecific antibody, with risvutatug rezetecan (GSK’227), GSK’s investigational B7-H3-targeting antibody-drug conjugate (ADC), in multiple solid tumor settings, including small cell lung cancer (SCLC).

Bellevue, Washington-based Savers Value Village (NYSE:SVV), a leading operator of for-profit thrift stores focused on second-hand apparel, home goods, and accessories, announced preliminary, unaudited net sales results for the fourteen-week fourth quarter and fifty-three-week fiscal year ended January 3, 2026, in connection with its participation in the ICR Conference January 12-14, 2026.

West Pharmaceutical Services (NYSE:WST), a leading provider of injectable packaging and delivery systems, announced it has entered into a definitive agreement to sell all manufacturing and supply rights for its SmartDose 3.5mL On-Body Delivery System, along with associated facilities, to AbbVie (NYSE:ABBV) for $112.5 million in cash at closing, subject to customary working capital and other adjustments.

Las Vegas-based Allegiant Travel Co. (NASDAQ:ALFT) and Minneapolis-based Sun Country Airlines Holdings (NASDAQ:SNCY) announced Sunday that Allegiant has agreed to acquire Sun Country in an all-cash-and-stock transaction valued at approximately $1.5 billion, marking the latest move in a wave of consolidation among smaller U.S. carriers.

Kyivstar (NASDAQ:KYIV), Ukraine's leading mobile operator and a subsidiary of VEON (NASDAQ:VEON), launched a 5G pilot network in the western city of Lviv on January 12, 2026, in collaboration with the Ministry of Digital Transformation of Ukraine.